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Metastasis is responsible for a majority of cancer-
related deaths, secondary to tumor progression to critical 
organs or to side effects resulting from therapeutic attempts 
at controlling tumor growth and spread. The progressive 
steps of the metastasis process include detachment of 
cancer cells from the primary tumor, disruption of the base-
ment membrane, invasion into the surrounding stroma, 
cancer cell entry into and transport through the vascular 
or lymphatic system to distal sites such as the liver, lungs, 
and brain, and extravasation, tumor cell proliferation and 
angiogenesis at distal sites [1–5]. A critical event in tumor 
cell invasion is degradation of the extracellular matrix (ECM), 
a complex network of extracellular macromolecules such 
as collagen, proteoglycans, fibronectin, laminin, and many 
other glycoproteins that acts as a barrier to the spread 
of cancer cells to distal sites by restricting tumor growth 
and invasion [6–8]. A special group of proteases, matrix 
metalloproteinases (MMPs), a family of zinc and calcium-
dependent proteolytic enzymes are crucial to invasion, 
migration, metastasis, and tumor genesis [8–10].
Over twenty different MMPs act on a broad spectrum 
of substrates, including collagen type I, II, III, IV, and 
stromyelin [11]. Among the many MMPs that have been 
identified, gelatinases, especially MMP-2 (gelatinase A) 
and MMP-9 (gelatinase B), are thought to a play a key 
role in degradation of type IV collagen and gelatin, the 
two main components of ECM. MMP-2 and MMP-9 are 
secreted in their latent zymogenic form, 72kDa and 
92kDa, respectively. MMP-2 and MMP-9 are cleaved 
by other MMPs or proteases to yield the activated forms 
of 68kDa, 58kDa, and 54kDa for MMP-2, and 84kDa for 
MMP-9. Increased expression of MMP-2 and  MMP-9 is 
reported in many human tumors, including ovarian, 
breast and prostate tumors, and melanoma [12–14]. A 
significant association has been reported between tumor 
aggression and increased levels of MMP-2 and MMP-
9 in many experimental and clinical studies [8, 9, 15–19].
The aim of this study was to examine the relation-
ship between Matrigel invasion and MMP-2 and MMP-
9 secretion in human cancer cell lines exhibiting various 
patterns of MMP-2 and MMP-9 expression treated with 
various doses of NM. Since expression of MMPs is highly 
regulated by cytokines and signal transduction pathways, 
including those activated by phorbol 12-myristate 13-ac-
etate (PMA), the effect of PMA on MMP-2 and MMP-
9 expression in several human cancer lines was assessed.
METHODS AND MATERIALS
Cancer cell lines and reagents. Forty-two dif-
ferent cancer cell lines were selected based on dif-
ferent patterns of MMP-2 and MMP-9 expression, 
and included carcinomas, sarcomas, and leukemias 
(Table 1). The cancer cell lines and their recommended 
media were purchased from ATCC (Manassas, VA, 
USA). Penicillin, streptomycin, PMA, and fetal bovine 
serum (FBS) were obtained from Sigma (St. Louis, MO, 
USA). All other reagents used were of high purity and 
were obtained from Sigma, unless otherwise indicated.
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Table 1. List of cancer cell lines classified by organ malignancy
Male Cancer
Prostate
       PC-3
       LNCAP
       DU-145
       22RV1
Testis
       NTER-2
Female Cancer
Breast
      MDA-MB-231
      MCF-7
Cervix
      HeLa
      DoTc2–4510
Ovarian
     SK-OV-3
Uterine
     SK-UT-1
Gastrointes tinal
Liver
      Hep-G2
      Sk-Hep-1
Pancreas
      MiaPaCa-1
Colon
      HCT-116
Lung and Me-
sothelioma
Lung
      A-549
      Calu-3
Mesothelioma
      MSTO-211H
Glioma
      A-172
      T-98
      LN-18
Head & Neck
Laryngopharynx
           FaDu
Tongue
           SCC-25
Thyroid
           SW579
Pediatric Sar-
coma
Osteosarcoma
          U2OS
          MMNG
Ewing’s Sarcoma
          SK-ES-1
Rhabdomyosar-
coma
   RD (embryonic)
Neuroblastoma
          SK-N-MC
Retinoblastoma
          Y-79
Adult Sarcoma
Fibrosarcoma
        HT-1080
Liposarcoma
        SW872
Synovial sarcoma
        SW982
Chondrosarcoma
        SW1353
Leukemia
        HL-60
        Jurkat
        Raji
Other Cancers
Bladder
        T-24
Melanoma
        A-2058
Kidney
        786–0
Composition of the nutrient mixture. The nutrient 
mixture (NM) was composed of the following in the ratio 
indicated: Vitamin C (as ascorbic acid and as Mg, Ca, 
and palmitate ascorbate) 700 mg;  L-lysine 1000 mg; 
L-proline 750 mg; L-arginine 500 mg;  N-acetyl cysteine 
200 mg; standardized green tea extract (derived from 
green tea leaves, was obtained from US Pharma Lab; the 
certificate of analysis indicated the following characteris-
tics: total polyphenol 80%, catechins 60%, epigallocat-
echin gallate (EGCG) 35%, and caffeine 1.0%); 1000 mg; 
selenium 30μg; copper 2 mg; manganese 1 mg.
Cell culture. Cancer cell lines were grown in recom-
mended media, supplemented with 10% FBS, penicillin 
(100 units/mL), and streptomycin (100 g/mL) in 24-well 
tissue culture plates (Coster, Cambridge, MA, USA). The 
cells were plated at a density 1 x 105 cells/mL and grown 
to confluency in a humidified atmosphere at 5% CO2 at 
37 C. Serum-supplemented media were removed and 
the cell monolayer was washed once with PBS and with 
the recommended serum-free medium. Cells were 
incubated with 1 ml of media at 37 C in a tissue culture 
incubator equilibrated with 95% air and 5% CO2. At near 
confluence, the cells were treated with the nutrient mix-
ture, dissolved in media and tested at 0, 10, 50, 100, 500, 
and 1000 μg/ml in triplicate at each dose. Parallel sets of 
cultures were treated with PMA (100 ng/mL) for induction 
of MMP-9. Control and PMA treatments were done in 
triplicates. The plates were then returned to the incuba-
tor. The conditioned media were collected separately, 
pooled, and centrifuged at 4 0C for 10 min at 3000 rpm 
to remove cells and cell debris. The supernatant was 
collected and used for gelatinase zymography, a highly 
sensitive assay of gelatinolytic enzymatic activity able to 
detect both pro and active forms of MMP-2 and MMP-9.
Gelatinase zymography. Gelatinase zymography 
was performed in 10% NOVEX Pre-Cast SDS Poly-
acrylamide Gel (Invitrogen Corporation) in the pres-
ence of 0.1% gelatin under non-reducing conditions. 
Culture media (20 L) were mixed with sample buffer 
and loaded for SDS-PAGE with tris glycine SDS buffer 
as suggested by the manufacturer (Novex). Samples 
were not boiled before electrophoresis. Following elec-
trophoresis the gels were washed twice in 2.5% Triton 
X-100 for 30 min at room temperature to remove SDS. 
The gels were then incubated at 37 C overnight in 
substrate buffer containing 50 mM Tris-HCl and 10 mM 
CaCl2 at pH 8.0 and stained with 0.5% Coomassie 
Blue R250 in 50% methanol and 10% glacial acetic 
acid for 30 min and destained. Upon renaturation of 
the enzyme, the gelatinases digest the gelatin in the 
gel and give clear bands against an intensely stained 
background. Protein standards were run concurrently 
and approximate molecular weights were determined 
by plotting the relative mobilities of known proteins.
Gelatinase zymograms were scanned using Ca-
noScan 9950F Canon scanner at 300 dpi. The inten-
sity of the bands was evaluated using the pixel-based 
densitometer program Un-Scan-It, Version 5.1, 32-bit, 
by Silk Scientific Corporation (P.O. Box 533, Orem, UT 
84059, USA), at a resolution of 1 Scanner Unit (1/100 of 
an inch for an image that was scanned at 100 dpi). The 
pixel densitometer calculates the optical density of 
each pixel (values 0 to 255) using the darkly stained 
background of the gel as a pixel value of 0. A logarithmic 
optical density scale was used since the optical density 
of films and gels is logarithmically proportional to the 
concentration. The pixel densitometer sums the opti-
cal density of each pixel to give a band’s density. In all 
graphs, band densities were reported as percentages of 
the sums of all pixels in a given lane (treatment) of a gel.
Matrigel  invasion. Invasion studies were conducted 
using Matrigel (Becton Dickinson) inserts in 24-well 
plates. Suspended in medium, cancer cells were supple-
mented with nutrients, as specified in the design of the 
experiment and seeded on the insert in the well. Thus 
both the medium on the insert and in the well contained 
the same supplements. The plates with the inserts were 
then incubated in a culture incubator equilibrated with 
95% air and 5% CO2 for 24 h. After incubation, the media 
from the wells were withdrawn. The cells on the upper 
surface of the inserts were gently scrubbed away with 
cotton swabs. The cells that had penetrated the Matrigel 
membrane and migrated onto the lower surface of the 
Matrigel were stained with hematoxylin and eosin and 
visually counted under the microscope.
Statistics. Pearson’s correlation coefficient was 
determined between pooled Matrigel invasion and 
MMP-2 and MMP-9 expression of cell groups using 
MedCalc Software (Mariakerke, Belgium).
RESULTS
Cell lines expressing only MMP-2 and resis-
tant to PMA induction of MMP-9. Ovarian cancer 
SK-OV-3, retinoblastoma Y-79, and thyroid carcinoma 
SW-579 exhibited only MMP-2 secretion and resis-
tance to PMA stimulation of MMP-9. NM inhibited 
Matrigel invasion in a dose-dependent manner in 
thyroid and ovarian cancer cells with 100% inhibition 
of thyroid cancer cells at NM 500 μg/mL and ovarian 
cancer cells at 1000 μg/mL Retinoblastoma cells did 
not demonstrate invasion through Matrigel. Pooled 
data of this group of cancer cell lines demonstrated 
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significant negative correlation (r = -0.77, p = 0.0003) 
between relative MMP-2 expression and inhibition of 
invasion through Matrigel, as shown in Fig. 1.
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Fig. 1. Correlation between MMP-2 secretion and Matrigel inva-
sion in cancer cells expressing MMP-2 only
Cell lines expressing only MMP-9. Burkitt’s 
lymphoma (Raji), cervical cancer (DoTc2–4510) and 
pancreatic cancer (MiaPaCa-1) cells showed dose-
dependent inhibition of invasion through Matrigel with 
NM treatment: 100% inhibition was seen in Burkitt’s 
lymphoma, pancreatic cancer, and in cervical cancer 
at 100, 500, and 1000 μg/mL NM, respectively. Basal 
and PMA-induced MMP-9 secretion was inhibited by 
NM in all three cell lines with total block of MMP-9 se-
cretion in Burkitt’s lymphoma and pancreatic cancer 
at 1000 μg/mL and of cervical cancer cell secretion at 
500 μg/mL. Pooled data of this group of cancer cell 
lines demonstrated significant negative correlation 
(r = -0.726, p = 0.003) between MMP-9 secretion 
and inhibition of invasion through Matrigel, as shown 
in Fig. 2.
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Fig. 2. Correlation between MMP-9 secretion and Matrigel inva-
sion in cancer cells expressing MMP-9 only
Cell lines expressing MMP-2 and MMP-9
Basal MMP-2 secretion with slight (10–20%) in-
duction of MMP-9 by PMA (Group A): glioblastoma 
(A-172), testis carcinoma.
Normal glioblastoma showed dose-dependent 
inhibition of Matrigel invasion and MMP-2 by NM 
with 100% block at 1000 μg/mL. PMA-treated glio-
blastoma cells showed dose-dependent inhibition of 
MMP- 2 and MMP-9 by NM, with 100% block of both 
MMPs at 500 μg/mL NM.
Basal MMP-2 secretion with moderate (40–50%) 
induction of MMP-9 (Group B): bladder carcinoma, 
cervical cancer (HeLa), hepatocellular carcinoma 
(Hep-G2), neuroblastoma, osteosarcoma (MNNG).
Normal cervical cancer cells showed dose-de-
pendent inhibition of MMP-2 with complete block of 
MMP-2 at 500 μg/mL NM. Matrigel invasion was inhib-
ited in a dose-dependent manner with total inhibition 
at 500 μg/mL NM. PMA-treated HeLa cells showed 
dose-dependent inhibition of MMP-2 and MMP-9 by 
NM, with 100% block of MMP-2 and -9 at 1000 μg/ml 
and 500 μg/mL NM, respectively.
Basal MMP-2 secretion with profound (70–90%) 
induction of MMP-9 by PMA (Group C): head and neck 
carcinoma (FaDu), leukemia (HL-60), lung cancer 
(A-549).
Normal FaDu cells showed dose-dependent inhibition 
of MMP-2 with complete block of MMP-2 at 500 μg/mL 
NM. Matrigel invasion was inhibited in a dose-dependent 
manner with total inhibition at 500 μg/mL NM. PMA-treat-
ed FaDu cells showed dose-dependent inhibition of MMP-
2 and MMP-9 by NM, with 100% block of MMP- 2 and -9 at 
1000 μg/ml and 500 μg/mL NM, respectively.
Basal MMP-2 greater than basal MMP–9 secretion 
with significant induction of MMP-9 by PMA (Group D): 
melanoma (A-2058), renal adenocarcinoma (786-0) 
mesothelioma (MSTO-211H), chondrosarcoma (W1353), 
osteosarcoma (U2-OS), rhabdomyosarcoma (RD), sy-
novial sarcoma (SW982) prostate cancer (PC-3).
Fig. 3 and 4 provide the zymograms and invasion 
photomicrographs for melanoma cell line A-2058, a 
representative cell line exhibiting basal MMP-2 greater 
than basal MMP–9 secretion with significant induction 
of MMP-9 by PMA. Normal melanoma cells showed 
dose-dependent inhibition of MMP-2 with complete 
block of MMP-2 at 1000 μg/mL NM. Matrigel invasion 
was inhibited in a dose-dependent manner with total 
inhibition at 500 μg/mL NM. PMA-treated melanoma 
cells showed dose-dependent inhibition of MMP-2 and 
MMP-9 by NM, with 100% block of MMP-2 and -9 at 
1000 μg/ml and 500 μg/mL NM, respectively.
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Fig. 3. Effect of NM on melanoma cells: gelatinase zymography: 
a, normal melanoma cells, legend: 1 — markers, 2 — control, 
3–7 -10, 50, 100, 500, 1000 g/mL NM; b, PMA (100 ng/mL)-
treated melanoma cells, legend: 1 — markers, 2 — control 
(100 ng/mL PMA), 3–7: 100 ng/mL PMA and 10, 50, 100, 500, 
1000 g/mL NM
Basal MMP-2 and MMP-9 equally expressed with 
PMA-induction of MMP-9 (Group E): fibrosarcoma 
(HT-1080), hepatocellular carcinoma (SK-Hep-1), 
tongue carcinoma (SCC-25), liposarcoma (SW872).
Normal liposarcoma cells showed dose-dependent 
inhibition of MMP-2 and MMP-9 secretion with com-
plete block of MMP-2 at 1000 μg/mL NM and MMP- 9 at 
500 μg/mL NM. PMA-treated liposarcoma cells showed 
dose-dependent inhibition of MMP-2 and MMP-9 by 
NM, with 100% block of MMP-2 and -9 at 500 μg/ml 
and 1000 μg/mL NM, respectively. Matrigel invasion was 
inhibited in a dose-dependent manner with total inhibition 
at 1000 μg/mL NM.
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Pooled data of this group of cancer cell lines 
 demonstrated significant negative correlation (r = 
-0.821, p < 0.0001) between MMP-9 secretion and in-
hibition of invasion through Matrigel, as shown in Fig. 5.
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Fig. 5. Correlation between MMP-2 and MMP-9 secretion and 
Matrigel invasion in cancer cells expressing both MMP-2 and MMP-9
Cell lines expressing no basal MMP-2 and 
MMP-9. Breast cancer (MCF-7) and (MDA-MB-231), 
T-cell leukemia (Jurkat), prostate cancer (Du-145), and 
uterine leiomyosarcoma (SK-UT-1) cell lines expressed 
no basal MMP-2, and MMP-9 only with PMA induction. 
Colon cancer (HCT-116) and prostate  adenocarcinoma 
(LNCaP) expressed neither MMP-2 nor MMP-9 even 
with PMA induction. The quantitative results of the 
effects of NM on Matrigel invasion of these cell lines 
are shown in Table 2 and the densitometric analyses 
of the effect of NM on MMP-9 secretion in normal and 
PMA-treated cells in this category are shown in Table 
3. Normal MDA-MB-231 cells showed no MMP-2 nor 
MMP-9 expression. PMA-treated breast cancer cells 
showed dose-dependent inhibition of MMP-9 by NM, 
with 100% block at 50 μg/mL NM. Matrigel invasion 
was inhibited in a dose-dependent manner with total 
inhibition at 500 μg/mL NM.
Table 2. Effect of nutrient mixture on inhibition of Matrigel invasion by 
cancer cell lines expressing neither MMP-2 nor MMP-9
Nutrient mixture treatment  
(μg/mL)
0 10 50 100 500 1000
Breast Cancer (MCF-7) 0% 58% 95% 100% 100% 100%
Breast Cancer (MDA-MB-231) 0% 25% 75% 98% 100% 100%
T-cell Leukemia (Jurkat) 0% 0% 10% 15% 72% 100%
Prostate Cancer (Du-145) 0% 56% 56% 66% 100% 100%
Uterine Leiomyosarcoma (SK-UT-1) 0% 0% 50% 70% 100% 100%
Colon Cancer (HCT-116) 0% 54% 66% 76% 76% 100%
Prostate (LNCaP) 0% 37% 59% 91% 91% 100%
Table 3. Effect of nutrient mixture on MMP-9 expression after PMA treat-
ment of cells that express neither MMP-2 nor MMP-9
Group C
Nutrient mixture treatment 
(μg/mL)
0 10 50 100 500 1000
Breast Cancer (MCF-7) 100% 100% 80% 10% 2% 1%
Breast Cancer (MDA-MB-231) 100% 14% 0% 0% 0% 0%
T-cell Leukemia (Jurkat) 100% 121% 106% 88% 0% 0%
Prostate Cancer (Du-145) 100% 97% 42% 10% 0% 0%
Uterine Leiomyosarcoma (SK-UT-1) 100% 90% 73% 13% 3% 0%
Colon Cancer (HCT-116) 0% 0% 0% 0% 0% 0%
Prostate Adenocarcinoma (LNCaP) 0% 0% 0% 0% 0% 0%
Lung Carcinoma (Calu-3) 0% 0% 0% 0% 0% 0%
Prostate Cancer (22RV1) 0% 0% 0% 0% 0% 0%
Pooled data of this group of cancer cell lines de-
monstrated significant negative correlation (r = -0.686, 
p < 0.0001) between MMP-9 secretion and inhibition 
of invasion through Matrigel, as shown in Fig. 6.
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Fig. 4. Effect of NM on melanoma cells: Matrigel invasion pho-
tomicrographs: a, control; b, 10 g/mL NM; c, 50 g/mL NM; d, 
100 g/mL NM; e, 500 g/mL NM
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Fig. 6. Correlation between MMP-9 secretion and Matrigel inva-
sion in cancer cells expressing MMP-9 only with PMA treatment
DISCUSSION
Numerous clinical and experimental studies have 
documented the increased levels of MMPs, especially 
MMP-2 and MMP-9 with cancer progression. Although 
the pattern of MMP expression can vary from tumor to 
tumor, specific MMPs increase in particular organ-related 
cancers. Recent clinical studies have focused on develop-
ing potential anti-neoplastic agents for specific cancers.
Due to the diagnostic and prognostic value of MMP-
2 and MMP-9 expression in cancers, specific focus has 
been directed to these MMPs. In part, this is due to the 
fact that MMP-2 and MMP-9 are type IV collagenases, and 
thus can degrade the major structural protein of ECM and 
basement membrane. Several studies have documented 
enhanced expression of these MMPs with tumor progres-
sion and metastasis [8, 10, 15–19].
Most MMPs appear to be secreted in inactive pro-
forms which are then activated extracellulary by either 
the plasminogen cascade system or by other members 
of the MMP family, such as MT-MMPs [11]. In this 
study, PMA was used as a model agent to stimulate 
the expression of MMP-9 by the cytokine pathway.
Different cancers demonstrate distinct patterns of 
MMP-2 and MMP-9 expression. For example, ovarian 
cancer, has been reported to exhibit elevated expres-
sion of MMP-9 compared to breast and bladder cancer 
[20]. Increased levels of MMP-2 expression have been 
reported in colon, pancreas, prostate, and skin cancer 
[12]. In our study, MMP-2 was constitutively expressed 
by most cell lines, whereas MMP-9 levels varied and usu-
ally could be induced by PMA. Interestingly, the prostate 
cancer cell lines LNCAP and colon cancer cell line HCT-
116 showed no MMP-2 or MMP-9 activity in either control 
or stimulated media. However, Matrigel invasion of these 
cell lines was evident as well as the dose-dependent 
inhibition of their invasion with NM treatment. It has been 
reported that co-culturing cancer cells that express no 
MMPs with stromal cells, a condition more representative 
of the clinical picture, leads to induction of MMPs. In vitro 
co-culture experiments of normal fibroblasts with tumor 
cell lines such as prostate, breast, colon, lung, and mela-
noma, have demonstrated high expressions of MMP-2 
and MMP-9 otherwise not seen; neither fibroblasts nor 
these cancer cell lines express MMP-2 and MMP-9 at 
substantial levels when monocultured [21–23]. These 
results suggest that co-culturing cancer cells with normal 
fibroblasts triggers alteration of the fibroblasts to support 
further cancer cell growth by secretion of MMPs, leading 
to ECM degradation, attachment to ECM components, 
and cellular motility.
Analysis of dose-dependent inhibition of MMP-2 and 
-9 by NM by the various cancer cell lines tested from all 
groups showed a significant correlation with NM dose-
dependent inhibition of Matrigel invasion by these cell 
lines. The cell lines most sensitive to inhibition of Matri-
gel invasion by NM were osteosarcoma (U2OS) and 
Burkitt’s Lymphoma (Raji), which exhibited complete 
blockage of invasion at 100 μg/mL, as shown in Table 4.
Table 4. Invasion inhibition effect of nutrient mixture: cell lines ordered 
according to nutrient mixture sensitivity
Nutrient mixture treatment 
(μg/mL)
0 10 50 100 500 1000
Liposarcoma 0% 0% 32% 44% 75% 100%
Synovial Sarcoma 0% 9% 28% 38% 79% 100%
Tongue Carcinoma 0% 0% 38% 40% 80% 100%
Hepatocellular Carcinoma (SK-Hep-1) 0% 42% 46% 53% 83% 100%
Chondrosarcoma 0% 0% 37% 68% 88% 100%
Leukemia (HL-60) 0% 0% 0% 15% 89% 100%
Ovarian Cancer 0% 32% 40% 59% 90% 100%
Glioblastoma (A-172) 0% 0% 23% 23% 93% 100%
Hepatocellular Carcinoma (Hep-G2) 0% 4% 4% 27% 97% 100%
Cervical Cancer (DoTc2-4510) 0% 10% 19% 86% 97% 100%
Mesothelioma (MSTO-211H) 0% 0% 27% 36% 100% 100%
Fibrosarcoma (HT-1080) 0% 40% 40% 50% 100% 100%
Lung Cancer (A-549) 0% 43% 43% 64% 100% 100%
Thyroid Carcinoma 0% 0% 42% 65% 100% 100%
Renal adenocarcinoma 0% 45% -- 68% 100% 100%
Cervical Cancer (HeLa) 0% 28% 52% 76% 100% 100%
Bladder Carcinoma 0% 36% 60% 81% 100% 100%
Testis Carcinoma 0% 32% 85% 85% 100% 100%
Head & Neck Carcinoma (FaDu) 0% 25% 24% 87% 100% 100%
Pancreas 0% 66% 66% 87% 100% 100%
Rhabdomyosarcoma (RD) 0% 75% 80% 92% 100% 100%
Melanoma 0% 30% 44% 95% 100% 100%
Osteosarcoma (MNNG) 0% 87% 97% 98% 100% 100%
Osteosarcoma (U2-OS) 0% 0% 74% 100% 100% 100%
Burkitt Lymphoma (Raji) 0% 63% 86% 100% 100% 100%
Thus, findings are significant as they indicate the 
importance of MMP secretion to achieve control of can-
cer invasion and metastasis. Those cell lines exhibiting 
moderate sensitivity (achieving total blockage at 500 μg/
mL NM) included thyroid cancer, FaDu, HeLa, melanoma, 
testes, bladder, fibrosarcoma HT1080, lung cancer and 
renal adenosarcoma.
CONCLUSION
In conclusion, the results clearly indicate that regard-
less of the MMP-2 and MMP-9 expression patterns 
of various malignancies, MMP expression modulation 
by NM is significantly correlated to NM modulation of 
Matrigel invasion of these cell lines. These findings are 
important as they demonstrate the major role of MMP-
2 and –9 in invasion and thus in potential metastasis 
by various cancer cell line groups, Furthermore, these 
results demonstrate the efficacy of the non-toxic NM in 
inhibiting MMPs and Matrigel invasion in vitro in cells from 
various malignancies and thus the potential of the thera-
peutic use of NM in treatment of various malignancies.
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